Richard Kefford
Overview
Explore the profile of Richard Kefford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
7833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piha-Paul S, Thein K, de Souza P, Kefford R, Gangadhar T, Smith C, et al.
Invest New Drugs
. 2021 Feb;
39(4):1047-1056.
PMID: 33594602
Background This was a phase I/IIa study to investigate the tolerability, efficacy and pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation of docetaxel. Methods The study was conducted in...
2.
Lebbe C, Italiano A, Houede N, Awada A, Aftimos P, Lesimple T, et al.
Target Oncol
. 2020 Nov;
16(1):47-57.
PMID: 33211315
Background: Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. Objectives: The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at...
3.
Delord J, Italiano A, Awada A, Aftimos P, Houede N, Lebbe C, et al.
Target Oncol
. 2020 Nov;
16(1):37-46.
PMID: 33170484
Background: The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-competitive MEK1/2 inhibitor. Objective:...
4.
Dey A, Manolios N, Long G, Carlino M, Kefford R, Schrieber L
Intern Med J
. 2020 Nov;
52(5):818-827.
PMID: 33135853
Background: Immunotherapy has revolutionised the treatment of many malignancies. Along with their success, there have been inflammatory and immune-related adverse events (irAE). There is a paucity of literature describing the...
5.
Carlino M, Menzies A, Atkinson V, Cebon J, Jameson M, Fitzharris B, et al.
Clin Cancer Res
. 2020 Jul;
26(19):5086-5091.
PMID: 32605909
Purpose: Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte-associated antigen 4 inhibitor demonstrated efficacy, but substantial toxicity, in melanoma. We present long-term results of part 1B...
6.
Bierbaum M, Rapport F, Arnolda G, Easpaig B, Lamprell K, Hutchinson K, et al.
Implement Sci
. 2020 May;
15(1):39.
PMID: 32460797
Background: Clinical Practice Guidelines (CPGs) synthesize the best available evidence to guide clinician and patient decision making. There are a multitude of barriers and facilitators to clinicians adhering to CPGs;...
7.
Bierbaum M, Braithwaite J, Arnolda G, Delaney G, Liauw W, Kefford R, et al.
BMJ Open
. 2020 Mar;
10(3):e035448.
PMID: 32205377
Introduction: Clinical practice guidelines (CPGs) are designed to reduce inappropriate clinical variation and improve the quality of care. Barriers to CPGs include a lack of awareness of CPGs, access to...
8.
Dummer R, Brase J, Garrett J, Campbell C, Gasal E, Squires M, et al.
Lancet Oncol
. 2020 Feb;
21(3):358-372.
PMID: 32007138
Background: Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAF-mutant, stage III melanoma in the phase 3 COMBI-AD trial. This prespecified exploratory biomarker...
9.
Hauschild A, Ascierto P, Schadendorf D, Grob J, Ribas A, Kiecker F, et al.
Eur J Cancer
. 2019 Dec;
125:114-120.
PMID: 31864178
Background: Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up...
10.
Menzer C, Menzies A, Carlino M, Reijers I, Groen E, Eigentler T, et al.
J Clin Oncol
. 2019 Oct;
37(33):3142-3151.
PMID: 31580757
Purpose: BRAF/MEK inhibition is a standard of care for patients with V600E/K-mutated metastatic melanoma. For patients with less frequent mutations, however, efficacy data are limited. Methods: In the current study,...